Pure-type clear cell carcinoma of the ovary as a distinct histological type and improved survival in patients treated with paclitaxel-platinum-based chemotherapy in pure-type advanced disease

Gynecologic Oncology

Volumn 94, Issue 1, 2004, Pages 197-203

  Ho, Chih Ming ^a,b,c   Huang, Yun Ju ^d   Chen, Tze Chien ^e   Huang, Shih Hung ^a   Liu, Fu Shing ^f   Chang Chien, Chan Chao ^g   Yu, Mu Hsien ^h   Mao, Tsui Lien ^d   Wang, Tao Yeuan ^e   Hsieh, Chang Yao ^d  

^a CATHAY GENERAL HOSPITAL   (Taiwan)

^b FU JEN CATHOLIC UNIVERSITY   (Taiwan)

^c TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^d NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^e MACKAY MEMORIAL HOSPITAL   (Taiwan)

^f TAICHUNG VETERANS GENERAL HOSPITAL   (Taiwan)

^g CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^h TRI SERVICE GENERAL HOSPITAL   (Taiwan)

Author keywords

Chemotherapy; Clear cell carcinoma; Ovarian cancer; Paclitaxel platinum

Indexed keywords

CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; PACLITAXEL; PLATINUM DERIVATIVE;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER REGISTRY; CANCER STAGING; CANCER SURVIVAL; CLEAR CELL CARCINOMA; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HUMAN; OVARY CARCINOMA; PRIORITY JOURNAL; PROGNOSIS;

ADENOCARCINOMA, CLEAR CELL; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CISPLATIN; COMBINED MODALITY THERAPY; CYCLOPHOSPHAMIDE; DOXORUBICIN; FEMALE; HUMANS; MIDDLE AGED; OVARIAN NEOPLASMS; PACLITAXEL; SURVIVAL RATE;

EID: 3242725237     PISSN: 00908258     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ygyno.2004.04.004     Document Type: Article

References (24)

1. Serov S.F., Scully R.E., Jobin L.H. Histological typing of ovarian tumors in international histological classification of tumors. vol. 9:1973;World Health Organization, Geneva
2. Russell P., Bannatyne P. Surgical pathology of the ovaries. 1989;Churchill Livingstone, New York
3. Russell P. Surface epithelial-stromal tumor of the ovary. Kurman R.J. Blaustein's pathology of the female genital tract. fourth ed.:1995;752-762 Springer, New York
4. Shevchuk M.M., Winkler-Monsanto B., Fenoglio C.M., Richart R.M. Clear cell carcinoma of the ovary: a clinicopathologic study with review of the literature. Cancer. 47:1981;1344-1351
5. Brescia R.J., Dubin N., Demopoulos R.I. Endometrioid and clear cell carcinoma of the ovary: factors affecting survival. Int. J. Gynecol. Pathol. 8:1989;132-138
6. McGuire W.P., Hoskins W.J., Brady M.F., Paul B.S., Kucera R., Partridge E.E., et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N. Engl. J. Med. 334:1996;1-6
7. Ho C.M., Chien T.Y., Shih B.Y., Huang S.H. Evaluation of complete surgical staging with pelvic and para-aortic lymphadenectomy and paclitaxel plus carboplatin chemotherapy for improvement of survival in stage I ovarian clear cell carcinoma. Gynecol. Oncol. 88:2003;394-399
8. WHO handbook for reporting results of cancer treatment. 1979;World Health Organization, Geneva
9. O'Brien M.E.R., Schofield J.B., Tan S., Fryatt I., Fisher C., Wiltshaw E. Clear cell epithelial ovarian cancer (mesonephroid): bad prognosis only in early stages. Gynecol. Oncol. 49:1993;250-254
10. Omura G.A., Brady M.F., Homesley H.D., Yordan E., Major F.J., Buchsbaum H.J., et al. Long-term follow-up prognostic factor analysis in advanced ovarian carcinoma: the Gynecologic Oncology Group experience. J. Clin. Oncol. 9:1991;1138-1150
11. Sherman M.E., Bitterman P., Rosenshein N.B., Delgado G., Kurman R.J. Uterine papillary serous carcinoma, a morphologically diverse neoplasm with unifying clinicopathologic features. Am. J. Surg. Pathol. 16:1992;600-610
12. Carcangiu M.L., Chambers J.T. Uterine papillary serous carcinoma: a study of 108 cases with emphasis on the prognostic significance of associated endometrioid carcinoma, absence of invasion and concomitant ovarian carcinoma. Gynecol. Oncol. 47:1992;298-305
13. Okada S., Tsuda H., Takarabe T., Yoshikawa H., Taketani Y., Hirohashi S. Allelotype analysis of common epithelial ovarian cancers with special reference to comparison between clear cell adenocarcinoma with other histological types. Jpn. J. Cancer Res. 93:2002;798-806
14. Sugiyama T., Kamura T., Kigawa J., Terakawa N., Kikuchi Y., Kita T., et al. Clinical characteristics of clear cell carcinoma of the ovary. Cancer. 88:2000;2584-2589
15. Goff B.A., Sainz de la Cuesta R., Muntz H.G., Fleischhacker D., Ek M., Rice L.W. Clear cell carcinoma of the ovary: a distinct histologic type with poor prognosis and resistance to platinum-based chemotherapy in stage III disease. Gynecol. Oncol. 60:1996;412-417
16. Kennedy A.W., Markman M., Biscotti C.V., Emery J.D., Rybicki M.S. Survival probability in ovarian clear cell adenocarcinoma. Gynecol. Oncol. 74:1999;108-114
17. Omura G.A., Bundy B.N., Berek J.S., Curry S., Delgado G., Mortel R. Randomized trial of cyclophosphamide plus cisplatin with or without doxorubicin in ovarian carcinoma: a Gynecologic Oncology Group study. J. Clin. Oncol. 7:1989;457-465
18. Hoskins W.J., Bundy B.N., Thigpen J.T., Omura G.A. The influence of cytoreductive surgery on recurrence-free interval and survival in small-volume stage III epithelial ovarian cancer: a Gynecologic Oncology Group study. Gynecol. Oncol. 47:1992;159-166
19. Recio F., Piver M., Hempling R., Driscoll D. Lack of improved survival plus increase in thromboembolic complications in patients with clear cell carcinoma of the ovary treated with platinum versus nonplatinum-based chemotherapy. Cancer. 78:1996;2157-2163
20. Gorai I., Nakazawa T., Miyagi E., Hirahara F., Nagashima Y., Minaguchi H. Establishment and characterization of two human ovarian clear cell adenocarcinoma lines from metastatic lesions with different properties. Gynecol. Oncol. 57:1995;33-46
21. Ohta I., Gorai I., Miyamoto Y., et al. Cyclophosphamide and 5-fluorouracil act synergistically in ovarian clear cell adenocarcinoma cells. Cancer Lett. 162:2001;39-48
22. Itamochi H., Kigawa J., Sultana H., et al. Sensitivity to anticancer agents and resistance mechanisms in clear cell carcinoma of the ovary. Jpn. J. Cancer Res. 93:2002;723-728
23. Itamochi H., Kigawa J., Akeshima R., et al. Mechanisms of cisplatin resistance in clear cell carcinoma of the ovary. Oncology. 62:2002;349-353
24. Itamochi H., Kigawa J., Sugiyama T., Kikuchi Y., Suzuki M., Terakawa N. Low proliferation activity may be associated with chemoresistance in clear cell carcinoma of the ovary. Obstet. Gynecol. 100:2002;281-287